Investigational Drug Information for SKLB1028
✉ Email this page to a colleague
What is the drug development status for SKLB1028?
SKLB1028 is an investigational drug.
There have been 9 clinical trials for SKLB1028.
The most recent clinical trial was a Phase 1 trial, which was initiated on March 24th 2021.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, Myeloid, and Leukemia. The leading clinical trial sponsors are CSPC ZhongQi Pharmaceutical Technology Co., Ltd. and [disabled in preview].
There are fourteen US patents protecting this investigational drug and nineteen international patents.
Summary for SKLB1028
| US Patents | 14 |
| International Patents | 19 |
| US Patent Applications | 61 |
| WIPO Patent Applications | 29 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 1 (2021-03-24) |
| Vendors | 36 |
Recent Clinical Trials for SKLB1028
| Title | Sponsor | Phase |
|---|---|---|
| A Study of SKLB1028 in Patients With Advanced Solid Tumor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
| SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1/Phase 2 |
| A Mass Balance and Biotransformation Study of [14C]SKLB1028 in Chinese Healthy Male Subjects | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 1 |
Clinical Trial Summary for SKLB1028
Top disease conditions for SKLB1028
Top clinical trial sponsors for SKLB1028
US Patents for SKLB1028
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SKLB1028 | ⤷ Start Trial | Pharmaceutical composition | Kyowa Kirin Co Ltd | ⤷ Start Trial |
| SKLB1028 | ⤷ Start Trial | Quinoline derivative for treatment of nasopharyngeal carcinoma | Chia Tai Tianqing Pharmaceutical Group Co Ltd | ⤷ Start Trial |
| SKLB1028 | ⤷ Start Trial | Substituted eneoxindoles and uses thereof | Gilead Sciences Inc | ⤷ Start Trial |
| SKLB1028 | ⤷ Start Trial | Substituted inhibitors of menin-MLL and methods of use | Wellspring Biosciences LLC , Kura Oncology Inc | ⤷ Start Trial |
| SKLB1028 | ⤷ Start Trial | Anti-CD73 antibodies and methods of use thereof | Agenus Inc | ⤷ Start Trial |
| SKLB1028 | ⤷ Start Trial | Compositions for the treatment of pathogenic- and/or chemical-induced lung injury and for the treatment of cancer and methods of using same | Duke University | ⤷ Start Trial |
| SKLB1028 | ⤷ Start Trial | Methods for treating hematological malignancies and Ewing's sarcoma | Wellspring Biosciences LLC , Kura Oncology Inc | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for SKLB1028
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| SKLB1028 | China | CN110691779 | 2037-03-24 | ⤷ Start Trial |
| SKLB1028 | China | CN117298275 | 2037-03-24 | ⤷ Start Trial |
| SKLB1028 | European Patent Office | EP3601249 | 2037-03-24 | ⤷ Start Trial |
| SKLB1028 | Japan | JP2020514388 | 2037-03-24 | ⤷ Start Trial |
| SKLB1028 | Japan | JP2023055735 | 2037-03-24 | ⤷ Start Trial |
| SKLB1028 | Japan | JP2025098022 | 2037-03-24 | ⤷ Start Trial |
| SKLB1028 | Japan | JP7628392 | 2037-03-24 | ⤷ Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
